FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Iowa Code §155A.13A requires any pharmacy outside Iowa that delivers, dispenses or distributes prescription drugs or devices to an ultimate user in Iowa to hold a nonresident pharmacy license, renewed each January 1. Applicants must show a valid home-state license and an inspection report less than 2 years old. The inspection must have been done while the pharmacy was operating, cover every part of the business used for Iowa, and be performed by or for the home-state authority if available; otherwise an NABP Verified Pharmacy Program report or a Board-preapproved inspection is accepted. Applicants also need evidence of corrective action. Unless licensed in Iowa, the pharmacist-in-charge must hold an Iowa nonresident pharmacist-in-charge registration ($75, annual) under 481 IAC 551.5. The pharmacy license fee is $135 a year (481 IAC 551.10). The Iowa Board of Pharmacy, within the Department of Inspections, Appeals, and Licensing, administers the license.

Iowa's pharmacy rules were moved in 2025. The old 657 IAC chapters, including ch. 19 (Nonresident Pharmacy Practice), ch. 20 (Compounding) and ch. 41 (Outsourcing Facilities), were rescinded, and new rules were adopted at 481 IAC chapters 550-557 (ARC 9337C/9338C, IAB 6/11/25, listed effective 7/16/25). The Administrative Rules Review Committee delayed them 70 days on 7/14/2025 and lifted the delay on 8/11/2025. Sources citing 657 IAC are out of date.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

481 IAC 552.22 (effective 2025) requires preparations compounded under section 503A to meet USP 795/797 (2023) and bars compounding essential copies of FDA-approved drugs unless a patient-specific clinical difference is documented or the drug is in shortage. Rule 552.22(3) expressly allows compounding for distribution to veterinarians for office use, and 552.21(5) covers labeling for non-patient-specific batch or veterinary office supply. No comparable provision for human-medicine practitioners was found. Separately, Iowa Code §155A.13C requires an Iowa outsourcing facility license for 503B facilities distributing sterile compounded human drugs without patient-specific prescriptions to Iowa practitioners. Whether a 503A pharmacy may supply human office stock was not confirmed; FDA views 503A compounding as patient-specific.

The former 657 IAC ch. 20 (Compounding Practices) was rescinded in 2025 (ARC 9346C) and replaced by 481 IAC 552.22 (ARC 9338C, IAB 6/11/25, listed effective 7/16/25, with a 70-day delay lifted 8/11/2025). Under 552.22(4), Iowa pharmacies that dispense compounded human preparations interstate must report yearly to the NABP information-sharing network. Confirm with the Iowa Board of Pharmacy (ibp-licensure@dial.iowa.gov, 515-281-5944).

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Iowa Code §155A.13C requires any FDA-registered outsourcing facility (21 U.S.C. §353b) that distributes sterile compounded human drug products without a patient-specific prescription to a practitioner or agent in Iowa to hold an Iowa outsourcing facility license first. The license is renewed each January 1 and costs $400 a year (481 IAC 551.14). Applicants must show current FDA outsourcing-facility registration and FDA inspection correspondence from the prior 5 years (Form 483s, warning letters, responses, corrective actions). They must also show a supervising pharmacist licensed in good standing in the facility's state, who is subject to a criminal-history check, and a satisfactory cGMP inspection within the prior 2 years by the home-state regulator or a Board-approved entity. A facility that also dispenses patient-specific prescriptions to Iowa patients must hold an Iowa pharmacy or nonresident pharmacy license. DIAL says a facility must stop distributing into Iowa immediately if its FDA registration lapses.

The DIAL page says outsourcing facilities that ship sterile compounded human drugs into, out of or within Iowa without patient-specific prescriptions need the license; the supervising-pharmacist background check fee is $45. The former 657 IAC ch. 41 (Outsourcing Facilities) was rescinded in 2025 and replaced by 481 IAC ch. 551/554.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Iowa is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Iowa Code Sec. 124.302 requires every person who dispenses controlled substances in Iowa to obtain and maintain a registration issued by the Board of Pharmacy, and 'dispense' includes prescribing and administering (Sec. 124.101). The Board's page (now under the Department of Inspections, Appeals, and Licensing) lists individual practitioners who prescribe to patients located in Iowa, including via telehealth when the practitioner is outside Iowa, and sets a $90 initial and biennial renewal fee (may be prorated to align with the professional license). The CSA registration number can be used to obtain the DEA registration, and the CSA becomes active after PMP registration. An individual needs only one CSA registration unless procuring or stocking their own controlled substances, in which case each location where stock is kept must be separately registered and an inspection is required first.

Rules were renumbered to 481 IAC chapters 551 and 553 under the DIAL reorganization. The Board page also notes that testosterone gel/injectable waste is RCRA hazardous pharmaceutical waste that must be incinerated. Per-location: separate CSA only where stock is kept.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Iowa Code 124.551A requires prescribers to register with the PMP when registering or renewing their controlled substance registration and to use the PMP database before issuing an opioid prescription, as set by their licensing board's rules; use is not required for inpatient hospice or long-term residential facility patients. The Board of Medicine rule (now 481-655.2(8), formerly 653-13.2) repeats that physicians must use the program before prescribing opioids and notes that hospital orders are not prescriptions for this purpose. The PMP is administered by the Iowa Board of Pharmacy.

Testosterone (C-III) is not caught. Iowa's 2025 rule reorganization moved Board of Medicine rules from agency 653 to 481 (e.g., 653-13.2 -> 481-655.2), so the TTAC citations to 653-13.2/653-19.4 are now transferred and 657-37.1 was rescinded 7/16/2025.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Iowa Code 147.107 allows physicians to dispense prescription drugs and controlled substances as an incident to practice. Non-judgmental tasks may be delegated only with the practitioner verifying accuracy in person (or via an automated system with a quality plan). A prescriber who dispenses (other than samples) must report that fact to the licensing board at least biennially and must provide a prescription on request or offer to send it to the patient's chosen pharmacy.

Answer is yes because only a biennial report (not a permit) is required.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Out-of-state physicians may consult with Iowa physicians without an Iowa license but otherwise need one (Iowa Code 148.2). The medical board's telemedicine rule generally expects an in-person interview and exam, but allows them by telemedicine when the technology is sufficient to establish an informed diagnosis as if done in person; a static internet questionnaire is not an acceptable exam for prescribing. No Iowa telehealth-specific Schedule III limit was found. IMLC: member.

Iowa renumbered professional-licensing rules in 2024-2025; the rule number is as CCHP cites it. For controlled substances such as testosterone, Iowa also requires a Board of Pharmacy controlled substance (CSA) registration, which applies to out-of-state practitioners prescribing to patients located in Iowa (Iowa Code 124.302; see the state_csr topic).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Iowa Board of Nursing's practice pages (checked 2026-09-23) cover RN/LPN role and scope and LPN IV courses but contain no statement on cosmetic injectables. Iowa's administrative rules were reorganized in 2025 and a Board of Medicine rule on cosmetic procedures could not be located.

Check with the Iowa Board of Nursing and Iowa Board of Medicine.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Iowa Board of Nursing's practice page lists LPN expanded-scope IV courses but no guidance on IV hydration businesses, individual exams, standing orders or mobile services (checked 2026-09-23).

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide rates Iowa 'Moderate', citing Iowa Code §147.2 and Attorney General Opinion No. 91-7-1; MedPath Compliance (reviewed 2026-06-20) lists Iowa as 'Yes' based on case law and an AG opinion.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Iowa Code ch. 157 (2026) requires estheticians who use microdermabrasion, certified laser products or IPL, and electrologists who use lasers or IPL for hair removal, to submit proof of additional training and certification for Board of Cosmetology approval. Cosmetologists and barbers licensed after 2005-07-01 may not use lasers or IPL. Chapter 157 licensees may use IPL only for hair removal, may not structurally alter tissue except for hair removal, and may use certified laser products only on surface epidermal layers. Laser or IPL hair removal on minors requires a parent or guardian and at least general physician supervision. Licensed physicians and nurses practising within their own licences are exempt from chapter 157.

PDF generated 2025-12-09 for the 2026 Iowa Code. Chapter 157 amended by 2025 Acts ch. 140. Delegation of lasers to nurses/unlicensed staff by physicians under medical board rules was not confirmed.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Iowa was not among them, but this research did not confirm its statutes. Iowa's CLIA state agency is Iowa CLIA Laboratory Program, State Hygienic Laboratory (shl-clia@uiowa.edu, 319-335-4500); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Iowa's rule. Iowa's lab regulator (CLIA state agency) is Iowa CLIA Laboratory Program, State Hygienic Laboratory (shl-clia@uiowa.edu, 319-335-4500). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Iowa is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Iowa does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.